185 related articles for article (PubMed ID: 25688802)
1. Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis.
Leoni C; Montagner S; Deho' L; D'Antuono R; De Matteis G; Marzano AV; Merante S; Orlandi EM; Zanotti R; Monticelli S
Eur J Haematol; 2015 Dec; 95(6):566-75. PubMed ID: 25688802
[TBL] [Abstract][Full Text] [Related]
2. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
[TBL] [Abstract][Full Text] [Related]
3. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
Zorzan E; Hanssens K; Giantin M; Dacasto M; Dubreuil P
PLoS One; 2015; 10(11):e0142450. PubMed ID: 26562302
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
7. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract][Full Text] [Related]
8. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
Greiner G; Witzeneder N; Berger A; Schmetterer K; Eisenwort G; Schiefer AI; Roos S; Popow-Kraupp T; Müllauer L; Zuber J; Sexl V; Kenner L; Sperr WR; Valent P; Mayerhofer M; Hoermann G
Blood; 2017 Jan; 129(3):371-382. PubMed ID: 27856463
[TBL] [Abstract][Full Text] [Related]
9. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
10. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Tefferi A; Levine RL; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Finke CM; Mullally A; Li CY; Pardanani A; Gilliland DG
Leukemia; 2009 May; 23(5):900-4. PubMed ID: 19262599
[TBL] [Abstract][Full Text] [Related]
11. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
[TBL] [Abstract][Full Text] [Related]
12. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
13. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
Horny HP; Sotlar K; Valent P
Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
[TBL] [Abstract][Full Text] [Related]
17. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
18. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
19. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
20. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]